hotspot -WSS

hotspot

author：hotspot 2025-10-01 21:33:26 - browse：1455

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： What we need to know about Arena Bioworks

WSS

A letter from the executive editor: The 2023 STATUS List

What affirmative action's end means to a medical student

Undocumented workers face uncertainty as immigration law takes effect in Florida

What affirmative action's end means to a medical student

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

SAMSHA loosens regulations on methadone treatment centers

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

23andMe had bad news about my health. I wish a person had delivered it

Undocumented workers face uncertainty as immigration law takes effect in Florida

George Santos makes 1st court appearance after pleading not guilty to 13 counts

What affirmative action's end means to a medical student

How to save PrEP access — and even expand it

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

BioMarin wins approval for gene therapy to treat hemophilia A

Do digital therapeutics have a future in medicine?

hotspot

What we need to know about Arena Bioworks

Vertex non

Canadians with cystic fibrosis outlive Americans by a decade

How Robert F. Kennedy Jr. distorted vaccine science

Lupron, used to halt puberty in children, may cause lasting health problems

UpToDate has a racism problem: Dr. Stanley Goldfarb

hotspot

hotspot

explore

focus